Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Public ClinicalTrials.gov record NCT04816604. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Study identification
- NCT ID
- NCT04816604
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
- Industry
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Interventions
- GB002 (seralutinib) Drug
- Generic Dry Powder Inhaler Device
Drug · Device
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 4, 2021
- Primary completion
- Nov 30, 2027
- Completion
- Nov 30, 2027
- Last update posted
- Apr 8, 2026
2021 – 2027
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Davis Medical Center | Sacramento | California | 95817 | — |
| Medical Corporation | Santa Barbara | California | 93105 | — |
| Mayo Clinic | Jacksonville | Florida | 32224 | — |
| Cleveland Clinic Florida | Weston | Florida | 33331 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Norton Pulmonary Specialists | Louisville | Kentucky | 40202 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| New York Presbyterian Hospital - Weill Cornell Medicine | New York | New York | 10065 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | — |
| INTEGRIS Baptist Medical Center, Inc. | Oklahoma City | Oklahoma | 73112 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| University of Utah Health | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04816604, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2026 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04816604 live on ClinicalTrials.gov.